Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: Preparation and detection in rat brain

Drug Development and Industrial Pharmacy

Volumn 41, Issue 12, 2015, Pages 2055-2068

  Hanafy, Amira S ^a   Farid, Ragwa M ^a   Elgamal, Safaa S ^b  

^a Pharos University of Alexandria   (Egypt)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Alzheimer's disease; Brain delivery; Chitosan nanoparticles; Complexation; Galantamine; Intranasal route

Indexed keywords

CHITOSAN NANOPARTICLE; GALANTAMINE; PLACEBO; POLYSORBATE 80; RHODAMINE B; CATION; DRUG CARRIER; NANOPARTICLE;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; BRAIN REGION; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; FLUORESCENCE MICROSCOPY; GELATION; HIPPOCAMPUS; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; NONHUMAN; PARIETAL CORTEX; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; ZETA POTENTIAL; ANIMAL; BRAIN; CHEMISTRY; DISEASE MANAGEMENT; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE MUCOSA; PIG; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ANIMALS; BRAIN; CATIONS; DISEASE MANAGEMENT; DRUG CARRIERS; MALE; NANOPARTICLES; NASAL MUCOSA; RATS; RATS, WISTAR; SWINE;

EID: 84949579969     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1062897     Document Type: Article

References (45)

1. Carmo Carreiras M, Mendes E, Jesus Perry M, et al. The multifactorial nature of alzheimer's disease for developing potential therapeutics. Curr Top Med Chem. 2013;13:1745-70.
2. Di Stefano A, Iannitelli A, Laserra S, et al. Drug delivery strategies for alzheimer's disease treatment. Exp Opin Drug Deliv 2011;8:581-603.
3. Rocha S. Targeted drug delivery across the blood brain barrier in alzheimer's disease. Curr Pharm Des 2013;19:6635-46.
4. Frey WH. Inventor neurologic agents for nasal administration to the brain (wo1991007947). US 1991.
5. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614-28.
6. Ong W-Y, Shalini S-M, Costantino L. Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr Med Chem 2014;21:4247-56.
7. Zargar V, Asghari M, Dashti A. A review on chitin and chitosan polymers: structure, chemistry, solubility, derivatives, and applications. Chem Bioeng Rev 2015;2:204-26.
8. Jain A, Gulbake A, Shilpi S, et al. A new horizon in modifications of chitosan: syntheses and applications. Crit Rev Ther Drug Carrier Syst 2013;30:91-181.
9. Bhattacharya S, Haertel C, Maelicke A, et al. Galantamine slows down plaque formation and behavioral decline in the 5xfad mouse model of Alzheimer's disease. PLoS One 2014;9:e89454.
10. Calvo P, Remunan-Lopez C, Vila-Jato JL, et al. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997;14:1431-6.
11. Subbiah R, Ramalingam P, Ramasundaram S, et al. N, n, n-trimethyl chitosan nanoparticles for controlled intranasal delivery of hbv surface antigen. Carbohydr Polym 2012;89:1289-97.
12. Moffat AC, Osselton MD, Widdop B. Clarke's analysis of drugs and poisons. London: Pharmaceutical Press; 2011.
13. Wang L, Li L, Sun Y, et al. In vitro and in vivo evaluation of chitosan graft glyceryl monooleate as peroral delivery carrier of enoxaparin. Int J Pharm 2014;471:391-9.
14. Wang X, Zheng C, Wu Z, et al. Chitosan-nac nanoparticles as a vehicle for nasal absorption enhancement of insulin. J Biomed Mat Res Part B Appl Biomater 2009;88:150-61.
15. Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2010;6:144-52.
16. Ma O, Lavertu M, Sun J, et al. Precise derivatization of structurally distinct chitosans with rhodamine b isothiocyanate. Carbohydr Polym 2008;72:616-24.
17. Hernandez CM, Gearhart DA, Parikh V, et al. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther 2006;316:679-94.
18. Migliore MM, Vyas TK, Campbell RB, et al. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2010;99:1745-61.
19. Spijker S. Dissection of rodent brain regions. In: Li KW, ed. Neuroproteomics. Berlin: Humana Press; 2011:13-26.
20. Pearson BL, Corley MJ, Vasconcellos A, et al. Heparan sulfate deficiency in autistic postmortem brain tissue from the subventricular zone of the lateral ventricles. Behav Brain Res 2013;243:138-45.
21. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57.
22. Rejman J, Oberle V, Zuhorn I, et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004;377:159-69.
23. Dong Y, Ng WK, Shen S, et al. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Carbohydr Polym 2013;94:940-5.
24. Fan W, Yan W, Xu Z, et al. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B 2012;90:21-7.
25. Abdel-Hafez SM, Hathout RM, Sammour OA. Towards better modeling of chitosan nanoparticles production: screening different factors and comparing two experimental designs. Int J Biol Macromol 2014;64:334-40.
26. Shu X, Zhu K. The influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. Eur J Pharm Biopharm 2002;54:235-43.
27. Alam S, Khan ZI, Mustafa G, et al. Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomed 2012;7:5705.
28. Sharma V, Ali M, Baboota S, et al. Preparation and characterization of chitosan nanoparticles for nose to brain delivery of a cholinesterase inhibitor. Indian J Pharm Sci 2007;69:712.
29. Janes KA, Fresneau MP, Marazuela A, et al. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 2001;73:255-67.
30. Hosseini SF, Zandi M, Rezaei M, et al. Two-step method for encapsulation of oregano essential oil in chitosan nanoparticles: preparation, characterization and in vitro release study. Carbohydr Polym 2013;95:50-6.
31. Traykova M, Trakov T, Hadjimitova V, et al. Antioxidant properties of galantamine hydrobromide. Zeitschr Naturforschung C 2003;58:361-5.
32. Bastida J, Viladomat F, Llabres JM, et al. Alkaloids from narcissus confusus. Phytochemistry 1987;26:1519-24.
33. Li H-Y, Ma G-E, Xu Y, et al. Alkaloids of Lycoris guangxiensis 1. Planta Med 1987;53:259-61.
34. Fazil M, Md S, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012;47:6-15.
35. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513-25.
36. Ali SW, Rajendran S, Joshi M. Synthesis and characterization of chitosan and silver loaded chitosan nanoparticles for bioactive polyester. Carbohydr Polym 2011;83:438-46.
37. Park C-W, Son D-D, Kim J-Y, et al. Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system. Int J Pharm 2012;436:32-40.
38. Qi L, Xu Z, Jiang X, et al. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 2004;339:2693-700.
39. Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Polon Pharm 2010;67:217-23.
40. Fröhlich E, Roblegg E. Mucus as barrier for drug delivery by nanoparticles. J Nanosci Nanotechnol 2014;14:126-36.
41. Das Neves J, Bahia MF, Amiji MM, et al. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Exp Opin Drug Deliv 2011;8:1085-104.
42. Brettschneider J, Del Tredici K, Lee VM-Y, et al. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci 2015;16:109-20.
43. Fjell AM, McEvoy L, Holland D, et al. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol 2014;117:20-40.
44. Sepulcre J, Sabuncu MR, Becker A, et al. In vivo characterization of the early states of the amyloid-beta network. Brain 2013;136:2239-52.
45. Serino S, Cipresso P, Morganti F, et al. The role of egocentric and allocentric abilities in alzheimer's disease: a systematic review. Ageing Res Rev 2014;16:32-44.